You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1386 EVOLVE-106, a T cell engager with integrated CD2 costimulation targeting B7-H4, is a precision therapy for estrogen and Her2 receptor low breast cancers

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1386 EVOLVE-106, a T cell engager with integrated CD2 costimulation targeting B7-H4, is a precision therapy for estrogen and Her2 receptor low breast cancers

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023316023
Dec 2023130019
Jan 20245508
Feb 20244804
Mar 20249405
Apr 202470018
May 20249406
Jun 20246105
Jul 202472018
Aug 202457011
Sep 20249008
Oct 2024124013
Nov 2024158014
Dec 202468016
Jan 2025104022
Feb 202537010
Mar 20250017
Apr 2025005
May 20250012
Jun 20251011
Total15790245